Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study-Reference-Cited by-同舟云学术

Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study

Published:2021-08 Issue: Volume:38 Page:100989
ISSN:2589-5370
Container-title:EClinicalMedicine
language:en
Short-container-title:EClinicalMedicine

Author:

Hsieh Szu-Min,Liu Wang-Da,Huang Yu-Shan,Lin Yi-Jiun,Hsieh Erh-Fang,Lian Wei-Cheng,Chen Charles,Janssen Robert,Shih Shin-Ru^ORCID,Huang Chung-Guei,Tai I-Chen^ORCID,Chang Shan-Chwen

Publisher

Elsevier BV

Subject

General Medicine

Reference21 articles.

1. WHO Director-General's Opening Remarks at the Mission Briefing on COVID-19–11 March 2020,2020

2. World Health Organization. COVID-19 Clinical Management: Living Guidance, 25 January 2021. World Health Organization. January 25, 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 (accessed March 3, 2021).

3. Rapid COVID-19 vaccine development;Graham;Science,2020

4. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation;Wrapp;Science,2020

5. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen;Pallesen;Proc Natl Acad Sci USA,2017

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein subunit vaccines: Promising frontiers against COVID-19;Journal of Controlled Release;2024-02

2. Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies;Biomedical Journal;2024-02

3. Achievements of COVID-19 vaccination programs: Taiwanese perspective;Journal of the Formosan Medical Association;2024-01

4. Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901-Beta SARS-CoV-2 Vaccine in Adults: A Phase I, Prospective, Randomized, Open-Labeled Study;Vaccines;2023-12-01

5. Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study;Journal of the Formosan Medical Association;2023-11